Grifols, S.A.

NASDAQ:GRFS

Drug Manufacturers - General

Healthcare
$8.47 +0.34%

+$0.03 today

Market cap
$7.17B
Beta
1.17
P/E (TTM)
14.7
EPS (TTM)
$0.61
Dividend yield
1.67%
52W Low $7.26High $11.14

Volume 0.59M

Average 0.69M

GRFS EBITDA Margin

EBITDA as a percentage of revenue.

Grifols, S.A.NASDAQ: GRFS

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 28.5%

EBITDA Margin was 28.5% in Q2 FY2026, up 5.3 pp from a year earlier. On a trailing-twelve-month basis it was 23.5%, up 1.4 pp year over year. Over 3 fiscal years it widened by 2.8 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 23.4% for the fiscal year ending Dec 2026, up from 22.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
28.5%+7.7 pp QoQ
Last fiscal yearDec 2025
22.5%+1.9 pp YoY
LTMJun 2026
23.5%+1.4 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+5.3 pp-6.3 pp-11.6 pp
1 year+1.9 pp+0.9 pp-0.9 pp
3 years+2.8 pp+3.5 pp+0.7 pp
5 years+3.7 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
22.5%
Year-over-year change
+1.9pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How GRFS compares with its peers on the latest reported figures

  • GRFS's LTM Jun 2026 EBITDA Margin of 23.5% is the 3rd highest of the 9 companies compared; the peer median is 20.0%.
  • Its year-over-year change of +1.4 pp is the 4th highest of 9, against a peer median of -2.4 pp.
  • Over three fiscal years its change of +2.8 pp compares with a peer median of -1.3 pp.
GRFS Competitors Peer median
EBITDA Margin for GRFS and competitors
Company Period LTM level YoY 3-year change
ADMAADMA Biologics, Inc.LTM Jun 202645.5% +11.1 pp+64.4 pp
TECHBio-Techne CorporationLTM Sep 202626.8% +8.6 pp-11.9 pp
GRFSGrifols, S.A.LTM Jun 202623.5% +1.4 pp+2.8 pp
BDXBecton, Dickinson and CompanyLTM Sep 202623.4% +1.3 pp+1.0 pp
ABTAbbott LaboratoriesLTM Sep 202620.1% -6.8 pp-0.3 pp
BIOBio-Rad Laboratories, Inc.LTM Jun 202619.9% -6.2 pp+208.5 pp
HAEHaemonetics CorporationLTM Jun 202619.3% -8.7 pp-2.2 pp
QDELQuidelOrtho CorporationLTM Mar 2026-20.7% -31.1 pp-51.4 pp
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026-26.6% +89.9 pp-148.5 pp
Peer median (excluding GRFS) 20.0%-2.4 pp-1.3 pp

Competitors are the stored peer set for GRFS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.93B6.06B6.59B7.21B7.23B
Cost of Revenue2.97B3.85B4.11B4.42B4.65B
Gross Profit1.96B2.21B2.48B2.79B2.58B
Gross Margin39.8%36.5%37.7%38.7%35.7%
Research & Development354.88M361.14M395.28M384.04M358.28M
Selling, General & Admin1.06B1.11B1.27B1.14B1.02B
Operating Expenses1.37B1.43B1.7B1.6B1.39B
Depreciation & Amortization359.77M410.98M446.42M437.9M432.24M
EBITDA944.03M1.19B1.17B1.48B1.62B
EBITDA Margin19.1%19.7%17.7%20.6%22.5%
Operating Income595.06M782.44M782.32M1.19B1.19B
Operating Margin12.1%12.9%11.9%16.5%16.4%
Interest Income11.55M33.86M62.43M48.05M32.66M
Interest Expense233.81M444.54M516.06M773.16M600.33M
Other Income / Expenses(244.61M)(444.42M)(575.3M)(748.02M)(596.49M)
Income Before Tax350.45M338.01M207.02M444M590.73M
Pre-Tax Margin7.1%5.6%3.1%6.2%8.2%
Income Tax Expense85.13M90.11M43.35M231.19M110.46M
Net Income188.73M185.04M42.32M156.92M386.13M
Net Margin3.8%3.1%0.6%2.2%5.3%
EPS (Basic)0.270.310.090.230.57
EPS (Diluted)0.270.310.090.230.57
Weighted Avg Shares681.56M679.81M679.76M680.02M680.58M
Weighted Avg Shares (Diluted)681.56M679.81M679.76M680.02M680.58M

Grifols, S.A.

NASDAQ:GRFS

Intrinsic Alpha fair value

Locked

Current Price

$8.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.